GH Research PLC (NASDAQ:GHRS – Free Report) – HC Wainwright cut their FY2024 EPS estimates for GH Research in a research note issued to investors on Monday, January 27th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.80) for the year, down from their prior forecast of ($0.76). HC Wainwright currently has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for GH Research’s Q4 2024 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($0.95) EPS, FY2026 earnings at ($0.98) EPS, FY2027 earnings at ($0.94) EPS and FY2028 earnings at ($0.49) EPS.
Separately, Canaccord Genuity Group lowered their price target on GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, November 18th.
GH Research Stock Performance
GH Research stock opened at $9.43 on Wednesday. The company has a market capitalization of $490.64 million, a PE ratio of -11.94 and a beta of 0.84. GH Research has a fifty-two week low of $6.00 and a fifty-two week high of $14.99. The firm has a 50 day moving average price of $8.38 and a 200 day moving average price of $8.92.
Institutional Inflows and Outflows
An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. raised its holdings in GH Research PLC (NASDAQ:GHRS – Free Report) by 1.3% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,686,689 shares of the company’s stock after buying an additional 85,000 shares during the period. RA Capital Management L.P. owned approximately 12.85% of GH Research worth $44,734,000 as of its most recent SEC filing. Institutional investors own 56.90% of the company’s stock.
About GH Research
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Recommended Stories
- Five stocks we like better than GH Research
- 10 Best Airline Stocks to Buy
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Learn Technical Analysis Skills to Master the Stock Market
- 3 Steel Stocks Soaring After Tariff Announcements
- Canada Bond Market Holiday: How to Invest and Trade
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.